Ferring Pharmaceuticals and Karolinska Institutet have agreed to a 5-year extension on a collaboration that is exploring the potential of the microbiome in reproductive medicine, women’s health and inflammatory bowel disease, according to a company press release.
“The extension of this partnership presents an exciting research opportunity, bringing together unique capabilities of Ferring, Karolinska Institutet and Rebiotix across the clinical development continuum in the microbiome space,” Lee A. Jones, Rebiotix founder and CEO, said in the release. “This, together with Ferring’s significant experience in reproductive medicine and gastroenterology, offers the potential to drive future research and development for the next generation of microbiome treatments needed to help more people build healthy families and live better lives.”
The extended collaboration is expected to include four studies of approximately 3,000 adults and children to investigate the microbiome’s role in IBD. Additionally, the collaboration is expected to consist of six reproductive health studies of approximately 6,000 women and babies to assess the microbiome’s role in recurrent pregnancy loss and preterm birth.
“This innovative public-private partnership demonstrates our ongoing, shared commitment to investigating the human microbiome,” Lars Engstrand, MD, director of the Center for Translational Microbiome Research at Karolinska Institutet, said. “It will support the expansion of Karolinska Institutet’s foundation of robust biological data and drive our understanding of the microbiome’s impact on important reproductive and gut health challenges.”